Benefits
Diuretic activity (traditional, limited human evidence)
Traditional Ayurvedic use as a diuretic (mutrala) for over 2,000 years. Animal pharmacology consistently shows diuretic activity comparable to thiazide-class diuretics in rat models. In diabetic nephropathy patients (proteinuria >500 mg/day) given punarnava in the diet for 6 months, urine protein and serum creatinine decreased. Rigorous human RCT confirmation is limited.
Hepatoprotective effects (preclinical models)
Multiple animal studies show Boerhavia diffusa extracts reduce liver enzyme elevation (ALT, AST, ALP) and bilirubin in models of acetaminophen-, CCl4-, country liquor-, and lantadene-induced hepatotoxicity. Mechanism involves antioxidant defense (SOD, catalase, GSH support), reduced lipid peroxidation, and direct membrane stabilization. Translation to human liver disease has not been rigorously studied with modern RCTs.
Nephroprotective in animal models of kidney injury
Evidence for B. diffusa nephroprotection spans acute kidney injury, chronic kidney disease, polycystic kidney disease, renal calculi, and urinary tract infection. Most evidence is in vitro (LLC-PK1 renal cells) and rodent models (cisplatin, gentamicin, paracetamol nephrotoxicity). A comparative trial in canine CRF showed comparable outcomes to enalapril. Human kidney disease translation remains largely traditional/Ayurvedic without modern RCTs.
Anti-inflammatory and antioxidant activities
Boeravinones, eupalitin, and other Boerhavia phytochemicals demonstrate NF-κB inhibition, COX-2 reduction, and direct radical scavenging in vitro and animal models. May contribute to broader rejuvenative claims (rasayana classification in Ayurveda). Clinical relevance for specific inflammatory conditions remains underexplored in human trials.
Mechanism of action
Diuretic activity via uncertain target
Animal evidence shows clear diuretic effect with increased urine output. Mechanism not fully characterized — possibly involves Na+/K+ pump modulation, increased renal blood flow, or direct tubular effects. Distinct from typical thiazide or loop diuretic mechanisms (lacks specific transporter inhibition). The rotenoids and punarnavoside may contribute. Effect appears mild and slow-onset compared to pharmaceutical diuretics.
Antioxidant protection of renal/hepatic tissue
Extracts upregulate endogenous antioxidants (SOD, catalase, GPx, GSH) and reduce lipid peroxidation (MDA) in kidney/liver models of toxin exposure. Eupalitin and other flavonoids contribute to direct scavenging. Combined with metal chelation effects, provides protection against drug-induced nephrotoxicity (cisplatin) in rodent models.
Anti-fibrinolytic and tissue-stabilizing
Punarnavoside is an antifibrinolytic glycoside — may stabilize tissue extracellular matrix and reduce fluid extravasation underlying edema reduction. Mechanism distinct from diuretic activity; complementary contribution to traditional 'shothahara' (edema-reducing) classification.
Calcium channel modulation (preclinical)
Some boeravinones and Boerhavia extracts demonstrate calcium channel antagonism in vitro — potentially relevant to cardiovascular and smooth muscle effects. Clinical significance unclear.
Clinical trials
Comprehensive review (Mishra S, Aeri V, Gaur PK, Jachak SM 2014, Biomed Res Int 2014:808302, doi:10.1155/2014/808302).
Ethnopharmacology, phytochemistry, and pharmacology review of Boerhavia diffusa across Indian medicinal systems and Western pharmacological literature.
Documented extensive preclinical evidence for: diuretic activity (rat models, comparable to thiazide diuretics), hepatoprotection (multiple toxin models), antidiabetic effects, anti-inflammatory action, immunomodulation. Noted limitation: relatively few rigorous human clinical trials despite extensive ethnobotanical use. Concluded modern clinical trial evidence is needed to translate the strong preclinical signal to clinical practice — a gap that persists today.
Animal study (Olaleye MT, Akinmoladun AC, Ogunboye AA, Akindahunsi AA 2010, Food Chem Toxicol 48(8-9):2200-2205, doi:10.1016/j.fct.2010.05.047).
Rats with acetaminophen-induced liver damage. Aqueous and ethanolic Boerhavia diffusa leaf extracts evaluated for antioxidant and hepatoprotective properties.
Pretreatment with B. diffusa extracts significantly decreased elevated alkaline phosphatase, lactate dehydrogenase, ALT, AST, and bilirubin levels in serum. Liver enzyme elevations also ameliorated. Protected against acetaminophen-induced lipid peroxidation. Concluded hepatoprotective property mediated through augmentation of antioxidant defenses. Animal evidence; not directly translatable to human clinical efficacy.
Comparative clinical evaluation (Naik AB, Devarakonda R, Nagayya N et al. 2015, Vet World).
CRF dogs (Spitz, German Shepherd, Labrador, etc., 8-12 years) randomized to Boerhavia root hydroalcoholic extract (Himalaya Punarnava — 250 mg per capsule) or enalapril 5 mg. 90-day comparative outcome assessment.
Outcomes with B. diffusa root extract treatment were comparable to enalapril for canine CRF. Advantages: faster improvement in Hb, potassium, phosphorus by day 30, urinary protein by day 90. Mortality: 5 dogs in enalapril group vs 2 in punarnava group died between 60-90 days. Veterinary trial — important proof-of-concept but not direct human evidence. Suggests therapeutic potential warranting human translation studies.